Skip to main content
. 2022 Sep 8;8:88. doi: 10.1038/s41421-022-00455-6

Fig. 5. Prevention and treatment effect of S-20-1 against mouse infection by HCoV-OC43 and SARS-CoV-2 Delta variant.

Fig. 5

a Schematic diagram of S-20-1 administration and HCoV-OC43 challenge. b In vivo efficacy of S-20-1 (80 mg/kg) against HCoV-OC43 infection in newborn mice. Viral RNA expression level in brain tissue of mice in each group on the 4th day post-infection was detected. c Schematic diagram of S-20-1 administration and SARS-CoV-2 challenge. d Viral RNA expression level after incubation of S-20-1 with authentic SARS-CoV-2 Delta on Caco-2 cells. e, f In vivo efficacy of S-20-1 (60 mg/kg) against SARS-CoV-2 Delta variant infection in hACE2-transgenic C57BL/6 mice. Viral RNA expression level in mouse brain (e) and lung (f) of each group on the 4th day post-infection was detected. These data were analyzed by Student’s t-test (d) and One-way ANOVA (b, e, f).